<SEC-DOCUMENT>0001493152-19-000216.txt : 20190107
<SEC-HEADER>0001493152-19-000216.hdr.sgml : 20190107
<ACCEPTANCE-DATETIME>20190107070041
ACCESSION NUMBER:		0001493152-19-000216
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190107
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190107
DATE AS OF CHANGE:		20190107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		19512135

	BUSINESS ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported): January 7, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>MICROBOT
MEDICAL INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-19871</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3078125</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
        or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission
        </B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
        Number)</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25
        Recreation Park Drive, Unit 108</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hingham,
        Massachusetts 02043</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
    of Principal Executive Offices) (Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code: (781) 875-3605</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Former
Name or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
&sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;[&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
    FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 7, 2019, Microbot Medical Inc. issued a press release announcing anticipated operational and product milestones, including
a pivotal pre-clinical study and FDA pre-submission milestones, for 2019. The press release also summarized key 2018 operational
and product achievements. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this Item 7.01 and in Exhibit 99.1 of Item 9.01 is being furnished pursuant to Item 7.01 and shall not be deemed
to be &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this
Item 7.01 or Exhibit 99.1 of Item 9.01.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    9.01</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
    Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 0.1in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated January 7, 2019</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> &nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICROBOT
    MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    <FONT STYLE="font-variant: small-caps">Harel Gadot</FONT></I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Chairman</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
January 7, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="logo_001.jpg" ALT="" STYLE="height: 139; width: 275"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 106.2pt; text-indent: 35.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Announces FDA Pre-Submission Milestones for 2019</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Regulatory
Pre-Submission of the Self-Cleaning Shunt (SCS</I></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>TM</SUP><FONT STYLE="font-weight: normal"><I>)
Remains the Primary Operational Objective</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hingham,
MA &ndash; January 7, 2019 &ndash; Microbot Medical Inc. (Nasdaq CM: MBOT) announced today anticipated operational and product
milestones, including pivotal pre-clinical study and FDA pre-submission milestones, for 2019. The progress and successful execution
of key objectives in 2018, which included, among other things, Microbot&rsquo;s successful completion of the first phase of the
ongoing pre-clinical trials, the expansion of Microbot&rsquo;s portfolio of technologies and intellectual property and the strengthening
of Microbot&rsquo;s management team to meet the next phase of the Company&rsquo;s development efforts, are expected to position
Microbot to achieve the milestones listed below during 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
2018 Operational and Product Achievements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successfully
    completed and announced the results of two pre-clinical studies which were performed by leading U.S. academic institutions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 53.4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    in-vitro study, which was performed at Wayne State University, supports the SCS<SUP>TM</SUP>&rsquo;s potential as a viable
    technology for preventing occlusion in shunts used to treat hydrocephalus.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    in-vivo animal study, which was performed at Washington University in St. Louis School of Medicine, supports the safety profile
    of the Company&rsquo;s SCS<SUP>TM</SUP> as a CSF catheter.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demonstrated
    to leading neurologists for the first time, the activated SCS<SUP>TM</SUP> from a working prototype of its customized headset
    at the 2018 International Hydrocephalus Conference, held in Bologna, Italy in October 2018.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presented
    the results of the in-vivo animal study supporting the initial safety profile of the SCS&trade; at the 2018 International
    Hydrocephalus Conference, held in Bologna, Italy in October 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiated
    a pivotal pre-clinical study with a larger sample size to further evaluate the safety and efficacy of the SCS&trade; in the
    same in-vitro and in-vivo (animal) models. Microbot plans to use the findings for its future regulatory submissions in the
    US, Europe and other jurisdictions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    a novel technology from CardioSert Ltd., which the Company believes will bring added value to its current technologies.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthened
    its IP Portfolio with Global Patent Allowances resulting in a total of 30 patents granted and 18 patent applications pending
    approval.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Was
    awarded a non-dilutive grant from the European Commission to continue developing the SCS&trade;. The Commission&rsquo;s decision,
    in part, was based upon substantial demand for the SCS&trade; with the potential to create new market opportunities.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relocated
    its global Research &amp; Development operations to a state-of-the-art facility to meet the next phase of the Company&rsquo;s
    development efforts.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthened
    its management team and enhanced its Scientific Advisory Board with leading medical device expertise.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anticipated
2019 Operational and Product Milestones</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announce
    the results of an independent in-vitro study validating the operational effectiveness of the SCS<SUP>TM</SUP>.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    the pivotal pre-clinical study to further evaluate the safety and efficacy of the SCS<SUP>TM</SUP> being performed at Washington
    University in St. Louis School of Medicine and Wayne State University in the third quarter of 2019.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finalize
    the FDA regulatory pre-submission request for the SCS<SUP>TM </SUP>in the second half of 2019.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthen
    the balance sheet, including through non-dilutive sources of cash such as grants, to execute its near and long-term business
    plan.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Explore
    related market opportunities with significant medical needs and high procedure volumes that will benefit from the Company&rsquo;s
    technologies.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expand
    and protect the Company&rsquo;s global IP portfolio which creates barriers to entry.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Build
    out the Company&rsquo;s senior leadership.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&trade;,
which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes
in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot&rsquo;s
current technological platforms platforms, ViRob<SUP>TM</SUP>, TipCAT<SUP>TM</SUP> and CardioSert<SUP>TM</SUP>, are comprised
of three highly advanced technologies, from which the Company is currently developing its first product candidate: the Self Cleaning
Shunt, or SCS<SUP>TM</SUP>, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH. The Company also is
focused on the development of a Multi Generation Pipeline Portfolio (MGPP) utilizing all technologies. Further information about
Microbot Medical is available at http://www.microbotmedical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ViRob<SUP>TM</SUP> technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the
body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels,
the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages
as well as the ability to remain within the human body for prolonged time. To learn more about ViRob<SUP>TM</SUP> please visit
http://www.microbotmedical.com/technology/virob/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TipCAT<SUP>TM
</SUP>is a transformational self-propelled, flexible, and semi-disposable locomotive device providing see &amp; treat capabilities
within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly
suitable to navigate and crawl through natural &amp; artificial tubular lumens, applying the minimal necessary pressure to achieve
the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT<SUP>TM</SUP>,
visit http://www.microbotmedical.com/technology/tipcat/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CardioSert<SUP>TM
</SUP>technology contemplates a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal
surgery. The CardioSert<SUP>TM</SUP> technology features unique steering and stiffness control capabilities, and it was originally
developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during
percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as
peripheral intervention, neurosurgery and urology. CardioSert<SUP>TM</SUP> was part of a technological incubator supported by
the Israel Innovation Authorities (formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully
completed pre-clinical testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;expects&rdquo; and &ldquo;estimates&rdquo;) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development
and/or commercialization of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, need and ability
to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results
anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect
the businesses of Microbot Medical Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.&rsquo;s
filings with the Securities and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contacts:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Polyviou</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC
Group</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mpolyviou@evcgroup.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">732-933-2754</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">###</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !@ /8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH *:64$@GE0I/!/#$@=!SDJ>!R,9. 13JB;&YO<*A]F4-(!TYX;/I^-9U9
MN$;JWS_X= ?/7QJ_: \*?"$PV=[*EYKE]%/>I9-<V]M!:6%E'!]INKNXE9%B
M1/.C=+=V-S<Y8VT4@C('YV^)/^"COV749[?2M:\-L([F:)8X-+\136J;'*F-
M;]M*%K-*.XCF;<Y81!EVD_)/[?7BW5K[]HOQMHMS<S"P2?PA;FS8C:NGVEO?
M:D98QNW+%J*%H)A@'_1 K@;HM_Q)H7ASQ+XV\2>"/AUX(LX9/%OQ UJ#0=&6
M:)5L;#RK 7NIZS<^:T<0:SMH;B3:TBO,\6(5>1T5_P#-/Q8^D;XH8KQ.SKPZ
MX)C'"XG*>*\!P]@VJ.(C+$4L3%JK5FZ>(I\]13BO8SBE'D:YH3=Y/_1?PG^C
MMX?83PUR?Q"XUJ+%8;..%L=Q'7@ZE!PP\Z4E.C""G1FE&5.7[Z,KSYXRM4C%
MJ*_:+P__ ,%+2F4U73="U3:ZJ3%-<:)>R*QYPFO0Z= 2N0J;)FWHJN,[J^G_
M  ;^WE\'?$#0)KI\0>%S,%!N;C2[G6M+C=CC,NH^&X-6@@B&<M+<M#&A)WN
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M@/\ 9X^+^F_"3]@_X9^/_$=V\QL/"%E96J7+\WUZ_P!NDME#(@4.T-O,V6"
M_9F#$LREOP#_ &H_VXOB)\4->U>ZC\0W>C>&+68M)=61-]JDZ/FWAM=,M)R!
M:D2P2VQ2&,R3/$;E59)DD?LC322C?2*45:,8Z)):1C&,(JR22C%16BBDE8B4
MW4E*<MYMS>K>LG=ZR<I/5O64FVVVVVVW_39K/[:_[-FA79M+[XCV@97$<DD.
MB^*+B.-L#.]K?0I0H&>2Q5>"<XP3ZG\.?CI\(?BUYZ_#GQ_X?\4W%JK27-C8
MW,D>J01JRAI9=+O8K;4EA4NH,QM?)&X?/@@U_'W\)OV1?VV/VB="B\8>!OAV
MR^%;D&ZTW5O'/BI])FU>&5W,<L&F6EPUU!),59L7L$*Y.X[%85]Q_P#!.[]G
M[]ISX,_MP:9'\3_ &O>%-*D^'&O6>HZM8R6FH^'-1C%W$WDG4;6[N&DF (19
M)XXWBVF+_EF#4O1M=FQ']$GBCXW?"7P9JD^B^*?B!X9T/5H2BS:??:A''>0L
M^W8)X5#R0[U963S0@9&60?NW5C1TOX]?!_6-.U35M)^(WA34M/T>Z%GJ<EGJ
MD-S-:W!4.L4EI$7O"Q5E93';NK@@HQ!%?R^_\%(M>UVQ_:Q^)-MIVL:A86\;
M:6Z007"/$ NEZ4$5#)$[ABN#(2Q'F%P#@ #XY\(?$7XP74EY\&O@[HVJ^+/&
M_P 3;Y]3O+'25M6U2YBTY$MVGU+4KJ:SM+"&*WCCCB)N(I)8E18EED#53IJ2
M34I1T7PV6O?5,S4W'FBU&2;?Q)NUWLM5H?U\#]LO]FB;Q+9^%'^)^F66N:GJ
M,6F:7;WNE>(;#[=?NJ!;9)-0TBT@AW,X"27$L4,J[9(Y'C=&;Z0EDM8(I-0>
M>TM[)8B\UY)-:I;QQ%%W.]\TPBA1@P;=NQAB02I%?R/_  V_X)^_MJ2_%'X1
MZO\ $GX7MH/@W2_&%GXD\0ZY)XQM+B?2+&QBCNY7:!M0N+MV:-?-D2&*8*[L
MB A0H^NOVX_V_?$%WJ8^&WPZNRFFZ;$=/$\D\\=K]FL8TL9KN]*Q6YNY)+F&
M62))$#+&45U !8PL/&#7L9.C&4_:5::C3JTJTW+GG.5.M&<:=2I4O4G4H\DW
M-\R2=F.45./*W*-.48*5.G.=)5%&-N6K4IN-6K3<6XNE4FZ?*W%)1T/T^_:+
MO?V+/B#ID^A_&/4]!U&[C;R[#4]'TZ[O-=L6(!,^G:_IUE=I*(B06#7+F-E,
M"QDQE%_-"Q\8ZY^SAJ\VI?LP_M!:5\4? <-PT]_\,?&1U'P_JR%6W)-90>,(
MO#^@^))((R5WIK5O=0.!#!!.8D=_R.\%:!^T5^TIXMO=$^$_A?Q9\4=4T^[\
MC5=:GN+?1M!TB>2".Y$ FN+VQL98XX)$5#9S3DJN)MMUYL:]-\3?@!^TK\ ?
M[.OOB]\-]4\*V&HS"+3O%6E3P>(-'CF?#,DMQ:7U^;#+LRRRW*PHLHD^<8%?
M#<1^&?#?%.*6:QIXK*N)L/)RPG$638NIEN?4JJ;<74S*C>OC\.G9_P!GYE];
MRZ27)/#2@W%_9<->(.?<,4/[(]I0S#A>I>&)X<S7"PS'(:E&]N2EEM?FH8"N
MH7C',,M>$S&&DH8F-1*2_I?_ &>_^"BWPB^*4EOX=\:W<OPR\<;O)EL?$/G1
M:/?7)E=7N+;4Y;=8;.TD(5@]]+;V<)D\FVN[B!(9YOG;_@LM=V^I?!OX27-E
M/;W5M<^*]=-M<VTJRV=QYNE6C1&WN@?)F\Y8G>+RW8RJ T>]60M^%7PU^(VA
M6?B+1]-^*=E/K?@G5+\VFH:O9"";Q%X2*GGQ!HMV[@:DT)(F.FW+-;L"4B5R
MH%?<'[7_ ,+?B/\ "/X;^ HO$GQ,F^(?P \6W)\2_#CQ2C7-YKFBZE<Z?%>0
M)K6D7.ZZ@!TVYCGD33;-[6V5A:[DFB:)?E%G?'OAUC'1XIRS%<<</K]Y4XDX
M?PU*GG^6X=)VK<1Y"ZE' 2IJFG/%YSDU>C2JR]I7PW#V%I\F%7U:R3P_X^H.
MKPIFU/@CB%SE3I\-\18JI6R#,<3=IT>&L_C2JX^%251J&%R;.:%:I1C[.A7X
MAQ555,2_@;]GRYM[7]I3X 7-S-';P#X@PW1EG81*L$B(%D;S-I7G(96 =""'
M5<5_8;XH_:K^ _@4QVVO^.[:&X5(DF2WTOQ!J$<16)"<RZ?I-W#P"-VUR V5
M8A@P'\8D&J:E\+M1L_'.DV]CKRV,_F:1J5G;3:T9[^X19$\FVMX[B;3KIVDW
M>1?16L@D+ +MQ7T+8_LI_P#!0'XQZ0_Q.E^"VNW>FZBG]K:<GB;7+70-1OK*
MZ4SQ2V.FC5X8V#0;6MHY45GA\HNBR,X'ZCD&?\/\5Y=2X@X?SO YMEV(G[&.
M797SXNM'$)?O*/\ :V(^HPH8FC*\,;A<TRG+'A:D:E/#5\PY(RG^=<09%GO"
MF:1X=X@R7,,JS%4O;RS#,_8X6%2CHU6PV4TYXCZU0G&\Z6)P^<U(UH2A4A3L
MTG_6=\//VGO@+\5+K^S_  /\3O#>K:GDK_9<\USH^HNP8J5ALM;MM.N+DY'_
M "[QR]1ZU[L'4DJ-V0"2"CC(!P2,J-PST*Y!X(R""?X,IY_'7@77[[3]6M?$
MG@;QEX;*17=I<PMI7B30KII5FCFAN=Z+=VLK2+-$\$L^ZVEB;.T@U_2%_P $
MS_V[+[XQ>%O$/PP^+FHK)X_^&FDIJ<&MSNWF>(?"RK<217SR%2#/:1Q#3IH7
M<74DMG)*EO)!+!*WLSA:4O<]F[N]+VOMO9N_P>V]G1]KR_"ZGLJ7/9R4(W2/
M)7*TG&HJT;>[5C3E256/2HJ4VYTU->\H2;E!/E;;5S]@K[4=/TR!KK4KZTT^
MU3[]S?7,-I O?YIKAXXU..Q8&OG_ ,3_ +6/P!\(326^M?$*RBFC?9MM],UZ
M^C=@ 2()['2;F"X R 6ADD4-E=VX$#\'/VV_^"@'BKQCXKO_  C\/;Q--TR.
MV+1SS.\EA9V\X*VTUU!(%\V;4%C>\C$2NUJ)EBNQ!,DD:_F1\./!?[2?[3VO
M74'PB\$>)OB*EC=I9ZMXHUK4XM$\/VM\UO'/)#IYO;ZPCN(E#;!)8?:(T=&C
MF=+A)8T2@NK?R&?V$^&_VROV:?%%VFGV'Q6T&UOW;;]FUJVUK0%5F<A%-WKF
MEZ=9%I!M=56X)PPXKZ3M+ZRO[:&\L;NWO;.YC$MO=VDR7-M<1MG:\%Q"SQ3!
ML''ENV<<5_#I\3?@A^T)\ [ZW@^,/P]UCP=%J"!=/U: IX@\-74TDGR?:-0M
MKJ^%K.SG;'YCQLA' V!37V+^Q%^WSXY_9Z\;:)X2\;:U?>)/A%X@URRTO4;#
M5;R34)O"][=,(%U#1[@&X:.R%VTCR6Y!99&<!/+"M0X+HV!^LW_!5_7-,U?X
M'R^&='U6"X\3:%XDT35]4TFTN?+O['2#$\DES< F-1\L\3K;*[7+I(KI RDD
M?S,^#;J=_B1\*I+JXNI8M*^(7A^ZDEG\V6.QM;:[A>>7*EF4*N78. Q).T$;
M<_IW_P %1/ 7QFM_C?XA^*.EV-RWP0^)5AX1.F^*;#4[;R;J4^&=$M_(N+-;
MTWJ$W%E=1[VLDB_=Y9QN!;\FKJ^O[&;3X/#UC=ZEK5_K%KINAZ?8.#/>ZC=,
ML=HDAF:,Q&<LK"2=HHE##+J.:.1=W^!FYM-K31O^MS^Z+P!\8/AAXV@33?"W
MCOP[K>I:7I=A/J5C;:A"M]91211)')=6LOE2PAV9=N] 2'0]'4DK^?S_ ()U
M?LP_M8^$/B-\1_&GQ+\ ZQX*L-=\':9IFG&36K&6;4;I-1L;MGF@L+K4!&T4
M$31H[;5DC565CN HK-Z-KLV6M4GW2'_\%ER!\<O!.3_S)"?^GK1Z^:O^"3.G
M0WO[<WAB22&!_LOPV\4RKYN]G67[+:E)XAM*(ZKA 00>,GFOHC_@M'?V5E\<
M? QO+RUM0_@=BIN9XH WE:GIERX!D=06$-O,X7.Y@F%!9D#?/?\ P2#U+3[S
M]N+1VL[ZTNUB^&7B!9&M;B*Y5&N;:WCA5FA9P"[QNI!.4*G>%XK9?"O3]!G[
M%?\ !7^WAN/V8=+,T;GR/B/I#QNWELRE]#UY%:-MQ=0S8X.&ZE@!@#^87PA:
M1WWQ,^$EC?()+:Y^+/@=9XTQM=8K^:/R'5L!P2F23E"23GFOZ>?^"P5U;VO[
M+%K<W,J000_$'P^99I24CC5M,U>(,[$ *OF7,*EC@+ORQ 5RO\P?@/5-+N?B
MY\'(;74M/NII/B_X3*0VM[;7,S+;ZA+-,PB@EDD*)'-&Q?;L.XJ"65@".R _
MM1^-UI G[-/Q#M1'&+2'X2:]AI!^[B%MH*R11^5&"?EBA;:8T(!B'0OAOXDO
M%T82TU]%4J%LM47:6WE&6W0/ACR09-Q&.BX Z"O[=OCI_P FU_$Z, ES\)_$
M8"@$GY_#ES$O0=Y"%_\ 'C\H)K^';Q;X@T*:V\0-%K&F.'MM3"A;VW+EIXU$
M2&/S-ZR,2%,;*'1LJZJ00"/7U?Y@?U<? 4$?\$MH,N9#_P *@UOYCG)_T=L#
MGG@?*/85_*SXM_X\/$O_ %Y7/_H:U_5+\!&!_P""7$*9P1\(M:7Y@47/E21\
M,^U2"Z, P)4@9!VD$_RB>*M>T1['Q"$U?36::TG2-!>VYD9VG$2H8_,\Q6,B
ME0K*IQ\V-I!(OM?XOT1#@F[ZZ_UV/W+_ &E]4UO2_P#@FK^RNUH\B:3?>(-,
ML=4DC$B)%'+HWB6.Q6>0#:WGZA,L2*-VW=N?:@8C\=OAYHFB^(_B?\&M.\4-
M##X>O/B?X4D\1>9NB LT;S94N2X&Z F5"Y^9=SE3EU=5_IQ^'/[/VF_M+_\
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M^">F_%B[^.-A\/\ 28?BA>O>W-QXH.5N9KF[@M;<F18SLXAMTC4JG"Q'=N+
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GTIM*VFG]=Q'T,/ZG]2:*%&!CW)/S%N223R>2,GC@8&   !14 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
